Drug Trial Radar · NCT00198991
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Last checked: Nov 19, 2026Latest source record: Aug 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,883
Actual
Start
Apr 2003
Primary completion
Jun 30, 2011
Study completion Jun 30, 2013
Sponsor
- Lead sponsor
- Goethe UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsche Krebshilfe e.V., Bonn (Germany); German Federal Ministry of Education and Research
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on the results of MRD evaluation.
Conditions
- Adult Acute Lymphocytic Leukemia
Interventions
CyclophosphamideDrug
Cytostatic drug
DexamethasoneDrug
Antileukemic drug
VincristineDrug
Cytostatic drug
DaunorubicinDrug
Cytostatic drug
AsparaginaseDrug
Cytostatic drug
MethotrexateDrug
Cytostatic drug
CytarabineDrug
Cytostatic drug
MercaptopurineDrug
Cytostatic drug
G-CSFDrug
Growth factor
VindesineDrug
Cytostatic drug
EtoposideDrug
Cytostatic drug
PrednisoloneDrug
Antileukemic drug
AdriamycinDrug
Cytostatic drug
ThioguanineDrug
Cytostatic drug
TeniposideDrug
Cytostatic drug
CNS irradiationProcedure
Cytostatic drug
Mediastinal IrradiationProcedure
Irradiation
Stem cell transplantation (SCT)Procedure
Stem cell transplantation
IdarubicinDrug
Cytostatic drug
FludarabineDrug
Cytostatic drug
CladribineDrug
Cytostatic drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Remission rateTime frame: day 46
- Remission durationTime frame: up to 10 years
- Disease free survivalTime frame: up to 10 years
- Overall survivalTime frame: up to 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Frankfurt, Medical Dept. II
Frankfurt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.